AG vs JHX

The company exhibits weak financial health with a Piotroski F-Score of 4/9, indicating marginal stability, and lacks an Altman Z-Score, raising concerns about financial distress risk. Despite strong recent price performance and robust revenue growth (95.10% YoY), the stock appears significantly overvalued with a P/E of 169.60 versus sector average of 26.34 and a Graham Number of just $4.23, far below the current price of $25.44. Earnings quality is poor, with a track record of missing estimates in 3 of the last 4 quarters and an average surprise of -24.17%. While balance sheet metrics like low debt/equity (0.08) and strong liquidity (current ratio 3.38) are positives, weak ROE (4.21%) and inconsistent profitability undermine long-term value creation.

JHX presents a stark contrast between deterministic value and growth expectations, with a Piotroski F-Score of 4/9 indicating stable but mediocre financial health and a Graham Number of $7.72 suggesting the stock is significantly overvalued. While revenue growth is robust at 30.10%, earnings have collapsed by 64.10% YoY, leading to an unsustainable trailing P/E of 90.79. The market is currently pricing in a massive recovery, as evidenced by the Forward P/E of 17.45 and a PEG ratio of 0.97. Despite strong analyst buy recommendations, the technical trend is bearish and the intrinsic value is severely disconnected from the current price.